Navigation Links
Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer

A breast-sparing surgery can be a suitable treatment mode for women diagnosed with breast cancer who harbour a mutation in their genes. //These patients should consider hormonal treatments to reduce their risk of a revival.

Those are the findings of a 10-year study led by researchers at the University of Michigan Comprehensive Cancer Center. The study authors found that women with the genetic mutation who had their ovaries removed or took the anti-estrogen drug tamoxifen had lower rates of breast cancer recurrence or new breast cancers in the other breast. Women who carry a mutation on the BRCA1 or BRCA2 gene are at an increased risk of breast cancer compared to women without the mutation. And once diagnosed with breast cancer, they face a higher rate of a second tumor occurring. Because of this, questions remain about whether these women should undergo breast-conserving surgery instead of mastectomy, which removes the entire breast.

In this study, published in the June 1 issue of the Journal of Clinical Oncology, researchers from 11 sites in the United States, Canada and Israel looked at 160 women with early breast cancer and the BRCA1 or BRCA2 gene mutations. The women were treated with lumpectomy, surgery to remove only the tumor, followed by radiation therapy. These women were compared to 445 similar women who were treated for breast cancer but did not carry the genetic mutations. After 15 years, both groups of women had similar rates of the tumor reoccurring in the same breast. But among the women with the BRCA1 or BRCA2 mutations, those who were further treated by having their ovaries removed, a procedure called oophorectomy, were less likely to have a recurrence. Similarly, tamoxifen dropped the risk of same-breast recurrence for the mutation carriers by 58 percent. Women with the genetic mutations had a significantly greater risk of developing breast cancer in the opposite breast than did the control group. After 15 years, 45 percent of the women with the mutation who had not undergone oopherectomy developed a second breast cancer in the other breast, compared to only 9 percent of those women without the genetic mutation.

Women with the mutation who took tamoxifen had a 69 percent reduction in breast cancer in the opposite breast. Among women who did not undergo oophorectomy, tamoxifen made a significant difference: 6 percent of those taking tamoxifen had a second cancer in the opposite breast after 15 years, compared to 54 percent of those who did not take tamoxifen. “For women with early stage breast cancer who are BRCA1 or BRCA2 carriers, our 10-year data suggest that oophorectomy or tamoxifen in women treated with breast conservation and radiation therapy help to reduce the risk of recurrences and new primary cancers in the treated breast to levels comparable to those observed in women with early stage breast cancer who are not BRCA1 or BRCA2 carriers,” says lead study author Lori J. Pierce, M.D., professor of radiation oncology at the U-M Medical School. “However, carriers must understand that the risk of breast cancer in the opposite breast still remained significantly greater than in women without a mutation. Thus, it is very important that women who choose breast preservation discuss with their doctors surveillance strategies not only of the involved breast but also in the opposite breast,” she says. Oophorectomy is a common procedure for women with the BRCA1 or BRCA2 gene mutations because it reduces the risk of ovarian cancer, which is also higher in women with these mutations. Tamoxifen is commonly prescribed to treat breast cancer that is responsive to estrogen.

Many women with the genetic mutations will have both their breasts removed before cancer develops as a preventive strategy. After breast cancer develops, bilateral mastectomy reduces the risk of it recurring by at least 90 percent. But studies have shown approximately the same number of breast cancer pa tients with the mutations choose mastectomy and breast conservation, suggesting considerable interest in breast conservation among this group of women. “We need to look to hormonal therapies that may lead to greater risk reductions than tamoxifen. For example, recent studies suggest comparable risk reductions with raloxifene and tamoxifen but fewer side effects with raloxifene. Studies are needed to assess the effect drugs such as raloxifene or aromatase inhibitors have in preventing second tumors in breast cancer mutation carriers,” Pierce says.

This year, 212,920 women will be diagnosed with breast cancer. About 1 in 300 people carry the BRCA1 or BRCA2 gene mutation. For information about breast cancer or genetic counseling, visit www.cancer.med.umich.edu/clinic/briskclinic.htm or call the Cancer AnswerLine at 800-865-1125 Source:Eurekaert
'"/>




Related medicine news :

1. Bariatric Surgery: Medicare, Will Now Cough Up For ‘Throwing Weight
2. Bariatric Surgery: A New Hope for Treating Obesity
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Treatment for Menieres disease
6. Treatment for pre-menstrual syndrome is ineffective
7. Better Treatment for obesity
8. Gene Treatment for Heart Disease
9. More People Seeking Treatment for Depression
10. Focused Treatment For Childhood Cancer
11. Inadequate Drug Treatment For Youth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing platform ... with the 2017 Women’s Choice Award. The identification by women of an effective ... 4 migraine sufferers are women. In a survey taken by the Women’s Choice Award ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Each of the past six years, Lightning Labels ... pictures of these labels and stickers, demonstrating the variety and creativity of their designs. Submissions ... label images came in. Now, it's time to announce the winners of the sixth annual ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: ... a B17 bomber named Edward Koontz. “To Walk Away” is the creation of published ... has published over two hundred manuscripts in chemistry and religion, as well as four ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Glimpses Of ... understanding of the world. “Glimpses Of Light” is the creation of published author, J.M. ... life in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Although Labor Day ... July, many communities have begun providing weekend displays, and numerous households celebrate the unofficial ... they can be downright terrifying for pets. , Kris Zambo, owner of ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , will ... Cell-Ess® Universal Titer Boost at the 9 th annual ... 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to ... ... Cell-Ess is the ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
Breaking Medicine Technology: